Brugada syndrome: Controversies in Risk stratification and Management by Nunn, LM et al.
 
www.ipej.org 400
Review Article  
Brugada syndrome: Controversies in Risk stratification and 
Management
Nunn LM, MRCP; Bhar-Amato J, MRCP; Lambiase PD, PhD, FRCP
The Heart Hospital, University College Hospital and Institute of Cardiovascular Sciences, UCL, 
16-18 Westmoreland Street, London W1G 8PH.
Address for Correspondence: Pier D. Lambiase PhD FRCP, Senior Lecturer and Consultant 
Cardiologist, The Heart Hospital, University College Hospital and Institute of Cardiovascular 
Sciences, UCL, 16-18 Westmoreland Street, London W1G 8PH. Email. 
pier.lambiase/at/uclh.nhs.uk
Funding and conflict of interest: Dr Bhar-Amato is supported by Heart Research UK; Dr 
Laurence Nunn is supported by UCL CBRC and National Institute of Heart Research
Abstract
In the 18 years since the first description of Brugada Syndrome in a small series of cardiac 
arrest survivors it has become evident that there is a marked spectrum in phenotype and 
prognosis. An internal cardiac defibrillator (ICD) is the only established therapy but is 
associated with significant morbidity. A number of registries have published their data, but risk 
stratification,   particularly   in   asymptomatic   patients,   remains   controversial.   This   article 
summarises the evidence to enable the clinician to make informed management decisions on an 
individual   basis.                                                                              
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Introduction
Brugada Syndrome (BrS) was first described in 1992 in 8 patients with recurrent episodes of 
aborted sudden death [1]. When characterising a new disease it is congruent that the most 
severe phenotype is described first. However, it is now clear that there is a marked spectrum in 
phenotype reflecting a variable degree of penetrance between individuals from those who are 
symptomatic with spontaneous type I ECG changes to asymptomatic individuals who only 
manifest characteristic ECG changes in response to a pharmacological challenge. This creates a 
challenge in risk stratifying patients and this review will discuss the current controversies in risk 
stratification and management of this condition.                                                                 
Prognosis of Brugada Syndrome                                                                                     
Prior to evaluating individual tools for risk stratifying patients it is important to appreciate the 
natural history of the disease and event rates. The following should be borne in mind when 
interpreting registry data and extrapolating this to individual patients.                           
Brugada   ECG   type                                                                        
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 10 (9): 400-409 (2010)Nunn LM, Bhar-Amato J, Lambiase PD, “Brugada syndrome:                          401 
Controversies in Risk stratification and Management”
Three types of Brugada ECG pattern are recognised either spontaneously or following 
pharmacological provocation (see  Figure 1). Currently only a type 1 ECG is regarded as 
diagnostic of the condition [2]. Of the major published registries two included patients with a 
non-type 1 ECG. Priori et al [3] included both sets of patients combined in the analysis, with 
Kamakura et al [4] analysing the two groups separately. It has been argued that including 
patients with a non-type 1 ECG improves prognosis because these individuals do not have the 
Brugada syndrome [5]. Whereas others would argue that excluding these patients results in 
falsely reassuring affected individuals who are still at risk of cardiac arrest [5], albeit a low risk. 
It has also been established that there can be a significant variation between diagnostic and non-
diagnostic ECG pattern in the same patient over time [6]. It is possible that a type 2 ECG 
represents a milder phenotype of the disease.
Figure 1: Three types of Brugada ECG pattern recorded in right praecordial leads V1- V3. Type 1 changes are 
characterised by coved ST-segment elevation of >2 mm (0.2 mV) followed by a negative T wave and is the only 
ECG phenotype that is currently regarded as diagnostic of Brugada Syndrome 2. Type 2 changes are characterised 
by saddleback ST segment elevation of >2 mm with a trough of >1 mm ST elevation and a positive or biphasic T 
wave and may represent a less severe phenotype. Type 3 is characterised by saddleback or coved appearance with 
an ST-segment elevation of <1 mm.                                                                                             
Difficulties in establishing a diagnosis                                                                                 
Establishing a diagnosis can be a challenge. The gold standard has been pharmacological 
provocation of type 1 ECG changes with a sodium channel blocker in those without 
spontaneous ECG changes [7]. There is however a discrepancy between the sensitivity of 
different agents employed [8], the specificity of ECG high lead placement is yet to be 
established and genotyping is only of limited help with an identifiable mutation present in only 
18-30%   of   cases   [2].                                                                              
Definition   of an  arrhythmic  event                                                                      
The arrhythmic end-point in the FINGER registry was defined as an appropriate ICD shock or 
sudden cardiac death. The authors highlight that with only 7 deaths occurring this was 
predominantly driven by ICD shocks, and the  two  are  not  synonymous [9].  Ventricular 
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tachyarrhythmias can be asymptomatic, terminate spontaneously and would otherwise remain 
undetected if the patient did not have an ICD. This could lead to an over-estimation of events in 
those with an ICD, skewing the data for the predictive value of PES as the majority of positive 
studies will result in ICD implantation compared to a minority of asymptomatic patients with 
negative PES who receive an ICD [9].                                                                                               
Risk   Stratification                                                                        
Table 1 summarises the event rates for patients in 3 groups: cardiac arrest survivors; those with 
a history of syncope; and asymptomatic patients. There has been a clear improvement in 
prognosis within each group since Brugada et al published their initial registry data. This is 
most strikingly observed in the asymptomatic group where the cardiac event rate has fallen 
from 10%/year in 1998 [10] to <1%/year in registries published over the last 5 years [4,9,11]. 
This most likely reflects the increased diagnosis of patients with a milder phenotype since its 
first description and referral of less severely affected individuals to international registries. 
Despite the differences between the groups, all concur that asymptomatic individuals have the 
best prognosis and those with a history of syncope or prior cardiac arrest have progressively 
higher risk. A meta-analysis by Gehi et al [12] reported the relative risk (RR) of an event 
(arrhythmic death, syncope or appropriate ICD shock) was 3.2 in symptomatic patients (history 
of syncope or aborted sudden cardiac death) compared to asymptomatic patients (p<0.001). RR 
in patients with a spontaneous rather than sodium channel blocker induced Type I Brugada 
ECG was higher (RR 4.65) as was male gender (RR 3.5). There was no increase in risk of 
events for those with a family history of SCD (p=0.97), SCN5a mutation (p=0.18) or 
inducibility at ventricular stimulation testing (p=0.27). Recently published results from the 
FINGER registry of 1029 patients (of which 657 had not been previously reported) had similar 
findings: symptoms and a spontaneous type 1 Brugada ECG were predictors of arrhythmic 
events, while familial history of SCD, presence of an SCN5A mutation, inducibility of 
ventricular arrhythmia and in this series gender, was not predictive of arrhythmic events [9]. 
Family history of sudden cardiac death despite not being predictive for events can still have a 
role in risk stratification. It is not unreasonable to offer an ICD to asymptomatic type 1 patients 
who have lost a close relative in this manner and their quality of life has suffered due to anxiety 
about their personal risk, however small [13]. It is imperative though to ensure such patients are 
consented appropriately particularly with regard to the morbidity associated with an ICD 
especially at a young age.
There is clear consensus for secondary prevention. Cardiac arrest survivors are at the highest risk 
and have a class 1 indication for an ICD [14]. There is a strong evidence base for the prognostic 
impact of syncope in Brugada syndrome and this is a class 11a indication for ICD [15]. Primary 
prevention for asymptomatic patients is a more contentious issue. Inducibility of ventricular 
arrhythmia is greatest amongst symptomatic compared to asymptomatic patients and a third of 
asymptomatic patients will have inducible ventricular arrhythmia [16] yet inducibility does not 
seem to equate to risk.                                                                                                     
The Brugada registry is the only dataset to show a prognostic impact of inducible ventricular 
arrhythmia at programmed ventricular stimulation. A meta-analysis of 15 studies comprising 
1217 patients conducted by Paul et al [17] did not support the use of ventricular stimulation in 
risk stratification. Direct comparisons between studies should be interpreted with caution due to 
heterogeneity amongst the patient populations and stimulation protocols employed. Single and 
dual site RV stimulation was employed with 2 or 3 extra-stimuli delivered. Some centres 
employed a particularly aggressive stimulation protocol continuing to deliver ventricular extra-
stimuli with a minimal coupling interval of <200msec. With aggressive stimulation VF can be 
induced in a normal heart [18] questioning the significance of a positive result in these patients 
under   such   circumstances.                                                                             
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Table 1. Summary of annual event rates (sudden cardiac death or documented VF) for patients 
in published registries based upon symptoms.
# Combined group of patients: cardiac arrest survivors and those with a history of syncope
* Combined group of asymptomatic patients and those with a history of syncope
These differences cannot explain the higher inducibility rates reported in Brugada series as only
single site stimulation at the right ventricular apex using minimal coupling interval >200msec 
was employed [19]. The difference has been ascribed to the inclusion of patients from the early 
series contributing the majority of events to later series [19]. Combined data presented from 
Kamakura et al [4] and the FINGER registry [9] shows the risk for arrhythmic events at 4 to 5 
years for asymptomatic patients with inducible VF is 2.6% and for asymptomatic patients with 
spontaneous type 1 Brugada ECG and inducible VF is 2% [20]. This compares to a risk for 
arrhythmic events of 3.5% for asymptomatic patients who are non-inducible and 3% in 
asymptomatic patients with spontaneous type 1 ECG Brugada pattern who are non-inducible 
[20].
Is a positive ventricular stimulation test useful?                                                         
PES is recommended in the 2005 Consensus document for asymptomatic patients with a 
spontaneous Type I ECG (class IIa) and asymptomatic patients with a drug induced Type I ECG 
and positive family history of sudden cardiac death (class IIb) [2]. There have been a number of 
studies published since the consensus document was drawn up all of which have failed to show a 
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prognostic impact from inducibility of ventricular arrhythmia. Univariate analysis of the data 
from the FINGER registry did show that those with inducible ventricular arrhythmia did have a 
shorter time to first arrhythmic event than those who were non-inducible (mean event rate of 
2.3% per annum compared to 1.2%) [9]. In a study of 220 patients with a type 1 Brugada ECG 
and ICD implanted there was an 1.5% annual rate of appropriate ICD shock in asymptomatic 
patients (86% of whom had an ICD implanted following induction of ventricular arrhythmia at 
testing)   [21].                                                                                    
Is a negative ventricular stimulation test useful?                                                                     
There is no role for ventricular stimulation testing in symptomatic patients as those who are 
noninducible still have a significant event rate [22]. Is a negative test in an asymptomatic patient 
reassuring? Priori reported a 14% false negative rate amongst those who were non-inducible [3] 
and on meta-analysis of the 23 patients who were asymptomatic and experienced an arrhythmic 
event, only 61% had inducible ventricular arrhythmia [17]. Analysis of the combined data from 
recently published Japanese and European registries reports a 3% risk of arrhythmic event at 4-5 
years in asymptomatic patients with a type 1 ECG who are non-inducible. Used in the appropriate 
patient a negative result may be reassuring enough to tip the balance away from ICD implant, but 
it is imperative that patients should be counselled beforehand what a positive and negative result 
would   mean   for   them.                                                                              
Finally, risk stratification is a fluid process and patients should be re-evaluated on a regular basis 
as phenotype does change with time and new data may materialize.                                          
Emerging Non-invasive Tools                                                                                     
A variety of non-invasive tools have been assessed which may have a role for risk stratification. 
Initial results are interesting but need to be borne out in larger cohorts of patients. It is unlikely 
that any single factor will have 100% sensitivity and specificity, rather the decision to implant an 
ICD in an asymptomatic patient will be based upon a global assessment of risk.             
Signal   Averaged   ECG   (SAECG)                                                                        
The presence of late potentials on SAECG has been shown to be more prevalent amongst 
symptomatic Brugada syndrome patients than asymptomatic patients  [23-25], associated with a 
higher incidence of arrhythmic events [23,24,26,27] and more frequent in patients with inducible 
VF at programmed ventricular stimulation [28,29].                                              
Fragmented   QRS                                                                                              
Morita et al [30] examined the appearance of multiple small spikes within the QRS complex, 
termed fragmented-QRS (f-QRS) recorded on 12 lead ECG with a 150Hz low pass filter in 115 
patients with Brugada syndrome and spontaneous type 1 changes at rest. F-QRS was identified in 
43% of patients, with a higher incidence in the VF group than asymptomatic patients or those 
with prior syncope (p=0.0069). Over a median of 25 months follow-up those patients with f-QRS 
and a history of syncope or VF had a higher incidence of recurrent syncope due to VF than those 
without f-QRS (p<0.001). Interestingly, the presence of late potentials (71% overall) or the 
inducibility of VF by programmed ventricular stimulation did not predict VF recurrence in this 
study.
Infero-lateral early repolarisation                                                        
Infero-lateral early repolarisation defined as at least 1mm of J point elevation present as QRS 
slurring or as a discrete notch inscribed on the S wave in any of the inferior (II, III or aVF) or 
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lateral (I, aVL) leads is present in 11% of BrS patients [31]. They were more likely to be 
symptomatic at first presentation (p=0.02) and have spontaneous type 1 ECG changes (p=0.05) 
[31]. A more conventional definition of infero-lateral early repolarisation was employed by 
Kamakura et al [4] which required the presence of J point elevation in at least 2 of the inferior (II, 
III or aVF) or lateral (I, aVL and V4-6) leads, resulting in a similar prevalence of 10% of 
Brugada patients (type 1 and non-type 1). Arrhythmic events occurred more frequently in those 
patients with infero-lateral early repolarization compared to those without(p<0.005), but there 
was no difference in risk between the patients with a type 1 ECG and a non-type 1 ECG [4].
Management of Brugada Syndrome                                                                                                   
General   Measures                                                                                  
All patients with Brugada syndrome should receive general advice regarding medications and 
lifestyle. A number of drugs are contra-indicated in patients with Brugada syndrome as they can 
provoke the development of Type I changes. A recent list has been published [32] together with a 
web site for continual updates to provide both physicians and patients with a comprehensive and 
easily accessible resource. Fever can elicit Type I ECG changes and should be managed 
aggressively. Patients are advised that sports activities should be limited to those as outlined in 
the ESC guidelines [33]. Given the dynamic phenotype and prognostic implications of a Type I 
ECG pattern, patients should have regular out-patient 12 lead ECG recording and 24hr Holter 
recording.
Internal Cardiac Defibrillator (ICD)                                                                                                 
The role of an ICD in primary and secondary prevention is discussed above. The benefits of an 
ICD may seem clear; however this has to be balanced against high complication rates, especially 
in young patients who will require several box changes and have endocardial leads in-situ 
potentially for many decades. Inappropriate shocks can frequently result from sinus tachycardia 
or supraventricular arrhythmia (recognised to have a higher incidence in Brugada Syndrome [34]) 
and this can result in a significant psychological impact especially in young, asymptomatic 
patients.
ICD outcome studies with a mean or median follow-up of 3.2yrs - 4yrs report appropriate shocks 
occurring in 8% - 15% of patients [21,35,36]. 0% - 15% of patients implanted for primary 
prophylaxis [21,35,36], with 22% - 45% of patients implanted following cardiac arrest [21,36]. 
Overall complications including inappropriate shocks are reported in 20% - 47% of patients 
[21,35,36]. Inappropriate shocks occur in 20% - 36% of patients caused by sinus tachycardia, 
supra-ventricular tachycardia, lead dysfunction or dislodgement and T wave over-sensing 
[21,35,36]. The subcutaneous ICD and absence of an endovascular lead may in the future prove 
to be an attractive alternative in Brugada syndrome to reduce complications. There is usually no 
class 1 indication for pacing in this population, but further data regarding the long term risks of a 
subcutaneous system are awaited.                                                                                             
Anti-arrhythmic   medication                                                                        
Isoproterenol has been successfully employed to suppress arrhythmic storm in Brugada syndrome 
[37-39]. A wider role for quinidine is being considered and a registry planned [40]. Quinidine 
inhibits  transient  outward  K+  current   (Ito),  preventing   phase  II   re-entry  and   ventricular 
fibrillation in the wedge preparation that mimics Brugada syndrome in vitro [41]. In vivo 
quinidine attenuates or normalises the Brugada ECG pattern [42-44], render patients non-
inducible at PES [42,44-46] and reduces the occurrence of further ventricular arrhythmia 
[36,42,44,46]. However its usefulness may be tempered by significant side effects, particularly 
gastro-intestinal disturbance and QTc prolongation.                                                                         
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Alternatives
Mapping and ablation of ventricular triggers for ventricular fibrillation in Brugada syndrome has 
been reported  [47] and in extreme  cases cardiac  transplantation is the last option [48].
Conclusions
There is a clear spectrum in phenotype in the Brugada syndrome. The role of ICD therapy in 
secondary prevention is established. It is the only effective management in primary prevention 
but patient selection can be difficult and the majority of patients screened will initially be 
asymptomatic. The tools for risk stratification are not precise but patient assessment can yield an 
estimate of risk for arrhythmic events and ICD therapy discussed with them on an individual 
basis.
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